Funded Biotechnology Startups in Wilmington
Among the 11 Wilmington, Delaware biotechnology entries shown, the largest disclosed round is NiKang Therapeutics at $200M on 2021-05-26.
Among the 11 Wilmington, Delaware biotechnology entries shown, the largest disclosed round is NiKang Therapeutics at $200M on 2021-05-26. That figure dwarfs the rest of the disclosed amounts, which top out at Prelude Therapeutics’ $90M (2026-04-21) and otherwise sit mostly between $1M and $22M, with DeepCyte and Liminatus each at $2M (2026-04-09 and 2026-06-03). Most funding events cluster tightly in 2026: six of the 11 rows have round dates in 2026, including multiple entries in June 2026 (iQure Pharma and Liminatus Pharma on 2026-06-03; NRx Pharmaceuticals also on 2026-06-03). Stage labeling is uneven: 7 of 11 rows are “Series Unknown,” and 2 of 11 are “undisclosed” on amount, leaving only a small set with specified stages (e.g., DeepCyte Seed at $2M on 2026-04-09; CorriXR Therapeutics Series A at $1M on 2025-08-19). The dated window spans 2021-05-26 through 2026-06-18, with the most recent entry iQure Pharma on 2026-06-18 (amount undisclosed).
Most recent rounds
11 shownRelated listings
Frequently asked
What stands out on size, and how does the top disclosed round compare to the next-largest amounts?
NiKang Therapeutics’ $200M (2021-05-26) is the only disclosed amount at that level; the next-largest disclosed round is Prelude Therapeutics at $90M (2026-04-21). After that, the rest of the disclosed amounts are much lower, including NRx Pharmaceuticals at $22M (2026-06-03) and several rounds at $15M or below (e.g., Synnovation Therapeutics $15M on 2023-12-14).
Are most rounds concentrated in a narrow time window based on the dates shown?
Yes. Six of the 11 rows have round dates in 2026, spanning from DeepCyte’s 2026-04-09 to iQure Pharma’s most recent 2026-06-18. There is also a pronounced June cluster: Liminatus Pharma ($2M) and NRx Pharmaceuticals ($22M) both dated 2026-06-03, alongside iQure Pharma on the same day (amount undisclosed).
How complete are the disclosed amounts and what share is missing or unclassified?
Two entries list “undisclosed” amounts: iQure Pharma (2026-06-18) and Ergo Bioscience (2024-10-31). On the series label, “Series Unknown” appears in 7 of 11 rows (including Liminatus Pharma 2026-06-03 $2M and Prelude Therapeutics 2026-04-21 $90M), so both stage and amount completeness are uneven.
What does the stage mix look like among rows with specified stages?
Specified stages are limited in this slice: DeepCyte is tagged “Seed” for $2M on 2026-04-09, and CorriXR Therapeutics is tagged “Series A” for $1M on 2025-08-19. The remainder is split between “Series Unknown” (7 of 11) and one row with a blank/unspecified series field (NiKang Therapeutics, dated 2021-05-26, $200M).
Any outliers worth focusing on beyond the largest round?
NiKang Therapeutics at $200M (2021-05-26) is the clearest size outlier, but there’s also a low-end set of small disclosed rounds: CorriXR Therapeutics at $1M (2025-08-19) and Switchpoint Bio at $5M (2026-03-10). Meanwhile, the high end above $50M is concentrated in a single 2026 event—Prelude Therapeutics at $90M (2026-04-21)—with no other disclosed rounds in that same range in the rows shown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.